MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202617064944 A) filed by Modex Therapeutics, Inc. on May 22, 2026, for Targeted Lnp Delivery.
Inventors include Lu, Yen-Chun; Eitas, Timothy, Kosarick; Jones, Nicholas, Edward; Brown, Leon; Chen, Hao; Shaik, Md, Munan; Wei, Ronnie, R.; Mascola, John, R.; Zerhouni, Elias, A.; Nabel, Gary, J.; Yang, Zhi-Yong; Wu, Lan; Liao, Sian; Leonard, Elissa, Kathleen; and Wei, Mohui.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3/antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.
Disclaimer: Curated by HT Syndication.
